Baidu
map

J Rheumatol:系统性红斑狼疮患者贫困收入比率与躯体功能的关联

2020-03-30 xiangting MedSci原创

这项研究结果表明,相对贫困阈值的收入较高与多个领域的躯体功能更好相关。

这项研究旨在探讨一个系统性红斑狼疮患者队列中,相对于贫困阈值的收入[贫困收入比率(PIR)]与自我报告躯体功能的关联。

研究使用来自乔治亚人抗狼疮组织(GOAL)744名参与者的横断面数据,而次要分析则使用嵌套试点研究中56名参与者的数据。初步分析使用多因素线性回归来估算PIR(分类为<1.00、1.00-1.99、2.00-3.99和≥4.00;PIRs越低表示越贫困)与躯体功能之间的关联(PF;按简表-12调查得出的子评分;范围0-100,分数越高表示功能越好)。次要分析总结了躯体功能的补充指标,表示为PIR的均值或百分数(分类为<1.00、1.00-1.99和≥2.00)。

总体而言,参与者的平均年龄48.0岁。男性占6.7%;黑人占80.9%;分别有37.5%、21.0%、29.6%和12.0%的参与者PIRs<1.00、1.00-1.99、2.00-3.99和≥4.00。总体平均PF得分为45.8(PIR<1.00、1.00-1.99、2.00-3.99和≥4.00参与者的得分分别为36.2、40.7、55.5和61.2)。经过调整,PIRs高仍与PF分数较高相关(β(95%CI))(2.00-3.99 vs. 1.00-1.99:10.9(3.3-18.6);≥4.00 vs. 1.00-1.99:16.2(6.4-26.0))。在次要分析中,PIRs较高也与客观躯体表现的分数较高相关。

这项研究结果表明,相对贫困阈值的收入较高与多个领域的躯体功能更好相关。因此有必要进一步研究多组分的功能评估,以制定个性化的治疗计划,从而改善预后的社会经济差异。

原始出处:

Courtney Hoge. Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus. J Rheumatol. March 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1740571, encodeId=46e51e4057180, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Fri Jan 15 17:18:18 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017216, encodeId=4a76201e216f2, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Fri Jun 05 13:18:18 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700884, encodeId=f62a1e008843b, content=<a href='/topic/show?id=3a83932466f' target=_blank style='color:#2F92EE;'>#躯体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93246, encryptionId=3a83932466f, topicName=躯体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3230261512, createdName=徐岩, createdTime=Mon Jul 20 21:18:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387396, encodeId=aae1138e39647, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436253, encodeId=1ffa14362531a, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1740571, encodeId=46e51e4057180, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Fri Jan 15 17:18:18 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017216, encodeId=4a76201e216f2, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Fri Jun 05 13:18:18 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700884, encodeId=f62a1e008843b, content=<a href='/topic/show?id=3a83932466f' target=_blank style='color:#2F92EE;'>#躯体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93246, encryptionId=3a83932466f, topicName=躯体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3230261512, createdName=徐岩, createdTime=Mon Jul 20 21:18:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387396, encodeId=aae1138e39647, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436253, encodeId=1ffa14362531a, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1740571, encodeId=46e51e4057180, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Fri Jan 15 17:18:18 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017216, encodeId=4a76201e216f2, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Fri Jun 05 13:18:18 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700884, encodeId=f62a1e008843b, content=<a href='/topic/show?id=3a83932466f' target=_blank style='color:#2F92EE;'>#躯体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93246, encryptionId=3a83932466f, topicName=躯体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3230261512, createdName=徐岩, createdTime=Mon Jul 20 21:18:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387396, encodeId=aae1138e39647, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436253, encodeId=1ffa14362531a, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1740571, encodeId=46e51e4057180, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Fri Jan 15 17:18:18 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017216, encodeId=4a76201e216f2, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Fri Jun 05 13:18:18 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700884, encodeId=f62a1e008843b, content=<a href='/topic/show?id=3a83932466f' target=_blank style='color:#2F92EE;'>#躯体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93246, encryptionId=3a83932466f, topicName=躯体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3230261512, createdName=徐岩, createdTime=Mon Jul 20 21:18:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387396, encodeId=aae1138e39647, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436253, encodeId=1ffa14362531a, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1740571, encodeId=46e51e4057180, content=<a href='/topic/show?id=ffdc9242430' target=_blank style='color:#2F92EE;'>#贫困#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92424, encryptionId=ffdc9242430, topicName=贫困)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=192134785590, createdName=654699882_84926997, createdTime=Fri Jan 15 17:18:18 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017216, encodeId=4a76201e216f2, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Fri Jun 05 13:18:18 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700884, encodeId=f62a1e008843b, content=<a href='/topic/show?id=3a83932466f' target=_blank style='color:#2F92EE;'>#躯体功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93246, encryptionId=3a83932466f, topicName=躯体功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3230261512, createdName=徐岩, createdTime=Mon Jul 20 21:18:18 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387396, encodeId=aae1138e39647, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436253, encodeId=1ffa14362531a, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 01 04:18:18 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
    2020-04-01 zhouqu_8

相关资讯

Ann Rheum Dis:IFN-K治疗系统性红斑狼疮的疗效和安全性

IFN-K诱导抗IFN-α2b抗体的中和,明显减少IFN基因标记,并且安全性可接受。

Ann Rheum Dis:系统性红斑狼疮的神经精神事件

NP事件最常发生在SLE诊断期间。尽管大多数事件可以消失,但其与HRQoL降低和死亡率升高相关。

NEJM:Anifrolumab治疗系统性红斑狼疮

研究认为,anifrolumab治疗后,高干扰素基因特征的系统性红斑狼疮患者达到复合终点的比例高于安慰剂组

Clin Exp Rheumatol:Framingham、ACC/AHA或QRISK3:哪一个适合系统性红斑狼疮的心血管风险评估?

与经典算法如Framingham和ACC/AHA相比,QRISK3将更多的SLE患者归类为未来10年出现CV疾病的高危人群。

Arthritis Rheumatol:SLEAR的rs13259960多态性影响系统性红斑狼疮易感性

这些发现揭示了rs13259960风险突变调节SLEAR表达并易患SLE的机制,并为SLE病因学提供了新见解。

Arthritis Rheumatol:热休克蛋白70 DNA疫苗保护F1小鼠免于罹患系统性红斑狼疮

HSP70 DNA疫苗通过诱导耐受性免疫应答和抗炎免疫反应来抑制鼠类的狼疮,而这些免疫反应与疾病症状减少和小鼠存活期延长相关。

Baidu
map
Baidu
map
Baidu
map